June 2024, Vol 5, No 2

Editor-in-Chief Milind M. Javle, MD, highlights takeaways from the 2024 Cholangiocarcinoma (CCA) Foundation Annual Conference.

The winners of the 2024 Innovation Grant, funded by the Bachrach Family Foundation, are announced.

Three presentations discussed the application of artificial intelligence learning– and machine learning-driven approaches to improve pathology, radiology, and drug discovery processes, showing strong potential for improving outcomes in patients with cholangiocarcinoma.

Benjamin L. Green, MD, presented Wilms’ tumor 1 vaccine novel adoptive cell therapy approaches for advanced solid cancers, including the role of immunotherapy in treating advanced cholangiocarcinoma.

Robin Katie Kelley, MD, presented the risks of developing cholangiocarcinoma due to the prevalence of pathogenic germline aberrations in biliary tract cancers.

Sudha Kodali, MD, MSPH, reviewed evidence supporting the role of liver transplantation in selected patients with intrahepatic cholangiocarcinoma.

Gregory B. Lesinski, PhD, MPH, presented novel adoptive cell therapy approaches for advanced solid cancers, including the role of immunotherapy in treating advanced cholangiocarcinoma.

Funda Meric-Bernstam, MD, presented various fibroblast growth factor receptor inhibitor resistance mechanisms present in cholangiocarcinoma.

Pedro M. Rodrigues, PhD, discussed novel noninvasive liquid biopsy strategies for biomarker discovery that may be utilized for early and differential diagnosis of cholangiocarcinoma.

Jennifer Tomlinson, MD, discussed novel preclinical research efforts focused on targeting the Yes-associated protein and transcriptional enhancer associate domain signaling axis to identify novel therapies for cholangiocarcinoma.